文献速递冠心病

糖蛋白IIb/IIIa抑制剂在急性心肌梗死及造影微血管阻塞中的应用:REVERSE-FLOW试验

Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial.
PubMed 文献 · Eur Heart J · 2024-01-01

REVERSE-FLOW试验随机纳入120例急性心肌梗死患者,直接PCI后TIMI血流≤2级,比较优化药物治疗联合或不联合GP IIb/IIIa抑制剂。主要终点梗死面积无显著差异,但治疗组CMR微血管阻塞(MVO)比例和范围显著降低,非致命性出血增加。

核心结论

  • 在急性心肌梗死直接PCI后造影微血管阻塞患者中,挽救性GP IIb/IIIa抑制剂未减少主要终点梗死面积,但降低了CMR衍生的MVO并增加非致命性出血。

研究设计与样本

  • 研究者发起的国际多中心随机对照试验REVERSE-FLOW,纳入120例急性心肌梗死直接PCI后TIMI血流≤2级的患者,随机接受优化药物治疗联合或不联合GP IIb/IIIa抑制剂。

关键数值与推荐

  • GP IIb/IIIa抑制剂用于急性心肌梗死直接PCI后造影微血管阻塞(无复流)的挽救性治疗,当前指南推荐为IIa类C级证据。
  • 治疗组62例中41例使用依替巴肽,21例使用替罗非班。
  • 人群特征:男性76.7%,中位年龄66岁,ST段抬高型心肌梗死73.3%。

临床怎么用

  • 对于急性心肌梗死直接PCI后出现造影微血管阻塞的患者,挽救性使用GP IIb/IIIa抑制剂可减少CMR定义的MVO,但需权衡非致命性出血风险。
  • 该治疗未显著缩小梗死面积,临床决策应个体化评估缺血与出血风险。

局限性

  • 样本量较小(120例),可能影响次要终点和安全性结果的稳健性。
  • 30天临床事件随访时间较短,长期获益与风险未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C). METHODS: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711. RESULTS: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n = 62) received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size assessed by CMR imaging was similar in both study groups [25.4% of LV mass (%LV) vs. 25.2%LV; P = .386]. However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; P = .017) and the extent of MVO (2.1%LV vs. 3.4%LV; P = .025) were significantly reduced in the GP IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non-life-threatening bleedings (22.6% vs. 6.9%; P = .016) without differences in all-cause mortality (4.8% vs. 3.4%; P = .703). CONCLUSIONS: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Eitel, Saraei, Jurczyk, et al. Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial. Eur Heart J. 2024. PMID: 39217605. doi:10.1093/eurheartj/ehae587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。